Aspirin Management Before PEG Procedure
Do not stop aspirin before PEG placement—aspirin should be continued throughout the procedure. 1
Key Recommendation
According to the 2021 BSG/ESGE guidelines, PEG is classified as a high-risk endoscopic procedure, but the management of aspirin depends critically on the patient's thrombotic risk profile, not the procedure risk alone 1.
For Patients on Aspirin Alone:
- Continue aspirin regardless of thrombotic risk status
- No interruption needed before PEG
- This applies to both low and high thrombotic risk patients
For Patients on Dual Antiplatelet Therapy (DAPT):
The approach differs based on thrombotic risk:
High Thrombotic Risk (coronary stents, recent stroke/TIA, peripheral vascular disease):
- Continue aspirin (strong recommendation, high quality evidence) 1
- Consult interventional cardiology regarding P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor) management
- If P2Y12 inhibitor must be stopped: discontinue 7 days before procedure 1
- Restart P2Y12 inhibitor 1-2 days after procedure 1
Low Thrombotic Risk:
- Continue aspirin (strong recommendation, low quality evidence) 1
- Stop P2Y12 inhibitor 7 days before procedure (strong recommendation, moderate quality evidence) 1
Evidence Supporting Aspirin Continuation
The guideline recommendations are reinforced by research evidence:
- A 2011 retrospective study of 990 PEG patients found no association between aspirin use (at any dose) and post-PEG bleeding 2
- The same study found that clopidogrel was also not associated with bleeding risk 2
- Interestingly, serotonin reuptake inhibitors (SRIs) were associated with 4-fold increased bleeding risk, not antiplatelet agents 2
A 2025 large database study confirmed these findings, showing no statistically significant difference in 7-day bleeding risk between patients on anticoagulants versus those not on anticoagulants, and no significant difference between DAPT and aspirin-only groups 3.
Clinical Algorithm
Step 1: Identify if patient is on aspirin
- If yes → Continue aspirin
Step 2: Identify if patient is on DAPT (aspirin + P2Y12 inhibitor)
- If yes → Proceed to Step 3
- If no → No medication changes needed
Step 3: Assess thrombotic risk
- High risk indicators:
- Coronary stents (especially <6-12 months for drug-eluting, <1 month for bare metal)
- Recent stroke/TIA
- Ischemic heart disease
- Peripheral vascular disease
Step 4: For high thrombotic risk
- Continue aspirin
- Mandatory cardiology consultation before stopping P2Y12 inhibitor
- If approved to stop: discontinue 7 days pre-procedure, restart 1-2 days post-procedure
Step 5: For low thrombotic risk
- Continue aspirin
- Stop P2Y12 inhibitor 7 days before
- Restart 1-2 days after procedure
Important Caveats
Post-Procedure Management:
- Resume any discontinued antiplatelet therapy 2-3 days after PEG depending on bleeding and thrombotic risk assessment 1
- Counsel patients about increased bleeding risk compared to those not on antiplatelets 1
Common Pitfall to Avoid:
Do not automatically stop aspirin because PEG is a "high-risk procedure." The 2021 guidelines explicitly state that aspirin continuation is recommended for high-risk procedures, with management decisions focused on P2Y12 inhibitors and anticoagulants, not aspirin 1.
Special Consideration:
If the patient is on aspirin for primary prevention only (no cardiovascular disease), consider discussing with the referring physician whether aspirin is truly indicated, as guidelines suggest permanent discontinuation may be appropriate in this specific scenario 1. However, for secondary prevention, aspirin must be continued.